BDBM268046 2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-1,3-thiazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine::US9549932, 78
SMILES: C[C@@H]1COCCN1c1cc(-c2cnc(C)s2)c2ccnc(-c3ccnn3C3CCCCO3)c2n1
InChI Key: InChIKey=YPMXSFANUORYGC-ADRQNKRLSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Serine/threonine-protein kinase ATR (Homo sapiens (Human)) | BDBM268046 (2-[(3R)-3-methylmorpholin-4-yl]-4-(2-methyl-1,3-th...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | 7.0 | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo... | US Patent US9549932 (2017) BindingDB Entry DOI: 10.7270/Q27S7QSC | |||||||||||
More data for this Ligand-Target Pair |